Richard Rutter, PhD
Head of Biology
With a drive to discover novel medicines, Richard is an experienced pharmacologist and drug discovery biologist. During his 20 years in the pharma and biotech industries he has established a track record of progressing drug discovery programmes from inception through to the clinic.
As Director of Biology at the GlaxoSmithKline Neurodegeneration Research Unit in Singapore, he was a member of the R&D leadership team managing a portfolio of preclinical programs from early target identification through to candidate nomination. More recently Richard was CSO at Auspherix Ltd, an early stage biotech developing a novel class of antibiotic.
In 2018, he co-founded NRG Therapeutics Ltd which is developing small molecule modulators of mitochondrial function for the treatment of Parkinson’s disease.
Richard studied Physiological Sciences at the University of Oxford before completing a PhD in molecular neuroscience at University College London.
